Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Prepaid Assets (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Prepaid Assets data on record, last reported at $13.5 million in Q4 2025.

  • For Q4 2025, Prepaid Assets fell 8.03% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $13.5 million, down 8.03%, while the annual FY2025 figure was $13.5 million, 8.03% down from the prior year.
  • Prepaid Assets reached $13.5 million in Q4 2025 per TARS's latest filing, down from $21.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $29.2 million in Q2 2025 and bottomed at $2.8 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $8.1 million, with a median of $6.0 million recorded in 2024.
  • The widest YoY moves for Prepaid Assets: up 388.5% in 2025, down 11.82% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $4.0 million in 2021, then grew by 17.85% to $4.8 million in 2022, then skyrocketed by 65.05% to $7.9 million in 2023, then surged by 86.2% to $14.6 million in 2024, then decreased by 8.03% to $13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $13.5 million in Q4 2025, $21.7 million in Q3 2025, and $29.2 million in Q2 2025.